Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hikma Pharmaceuticals's Enterprise Value is $5,597 Mil.
Hikma Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $607 Mil. Therefore, Hikma Pharmaceuticals's EV-to-EBIT ratio for today is 9.22.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Hikma Pharmaceuticals's Enterprise Value is $5,597 Mil.
Hikma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $845 Mil. Therefore, Hikma Pharmaceuticals's EV-to-EBITDA ratio for today is 6.62.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Hikma Pharmaceuticals (OTCPK:HKMPY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Hikma Pharmaceuticals's current Enterprise Value is $5,597 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $607 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Hikma Pharmaceuticals's EV-to-EBITDA for today is:
Hikma Pharmaceuticals's current Enterprise Value is $5,597 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $845 Mil.
Hikma Pharmaceuticals's current Enterprise Value is $5,597 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $3,349 Mil.
Hikma Pharmaceuticals's current Enterprise Value is $5,597 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $436 Mil.
Hikma Pharmaceuticals's current Enterprise Value is $5,597 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Hikma Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $119 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals Enterprise Value Related Terms
Hikma Pharmaceuticals Enterprise Value Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPY vs ZTS, UTHR, VTRS: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Enterprise Value falls into.
Hikma Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Hikma Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPY) has a Enterprise Value of $5,597 Mil as of Jul. 01, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Enterprise Value too high?
Hikma Pharmaceuticals' current Enterprise Value is $5,597 Mil. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Enterprise Value compare to ZTS and UTHR?
Hikma Pharmaceuticals' Enterprise Value of $5,597 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Enterprise Value is $5,597 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $57.15, compared to a current price of $41.23 — trading 27.9% below its estimated fair value. The current Enterprise Value is $5,597 Mil. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current Enterprise Value is $5,597 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $41.23 is trading 27.9% below its estimated GF Value™ of $57.15.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPY:
Enterprise Value: $5,597 Mil
GF Value™: $57.15 vs. price of $41.23 (27.9% below fair value)
No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score
Get the complete analysis for HKMPY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPY has been successfully added to your 
